Study on Treatment for Advanced Non-small Cell Lung Cancer with Specific Gene Changes After Targeted Treatment and Chemotherapy

Program Overview

This study is exploring how well different treatments work for patients with advanced non-small cell lung cancer (NSCLC) that has specific gene changes, known as actionable genomic alterations (AGA). These changes can be targeted by certain treatments to fight the cancer. The trial compares three treatment options: sacituzumab govitecan alone, ivonescimab alone, or a combination of both. Sacituzumab govitecan is a targeted therapy that delivers a toxic drug to cancer cells, while ivonescimab is an antibody that may boost the immune system and block tumor growth. The study aims to find out if these treatments can shrink tumors better than standard treatments.

Description

The main goal of this study is to compare how long patients live without their cancer getting worse when treated with sacituzumab govitecan and ivonescimab together versus each drug alone. Researchers will also look at how well each treatment works in shrinking tumors and how safe they are.

Participants will be randomly assigned to one of three groups:

• Group 1: Receive both sacituzumab govitecan and ivonescimab.
• Group 2: Receive sacituzumab govitecan alone.
• Group 3: Receive ivonescimab alone.

Each treatment cycle lasts 21 days, and patients will continue treatment as long as it is effective and side effects are manageable. Throughout the study, participants will have regular scans and blood tests to monitor their health and the cancer's response to treatment.

After finishing the study treatment, patients will have follow-up visits every 12 weeks or more often if needed, and then every 6 months for up to 3 years to check on their health and cancer status.

Eligibility Criteria

Locations